Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

HTG, BMS ink collaboration agreement
July 2016
SHARING OPTIONS:

TUCSON, Ariz.—HTG Molecular Diagnostics Inc. and Bristol-Myers Squibb have begun a research collaboration agreement to evaluate the potential of immuno-oncology molecular profiling in multiple tumors types. Per the terms of the agreement, HTG will grant access to its next-generation sequencing (NGS)-based HTG EdgeSeq system, and both companies will collaborate on the development of tools for use in molecular profiling research in immuno-oncology. No financial details were disclosed.
 
“We believe this collaboration will provide many benefits to Bristol-Myers Squibb’s immuno-oncology development programs and further add to HTG’s industry leadership in the development of NGS-based molecular diagnostic assays toward the goal of precision medicine. This collaboration is the result of a long-standing Bristol-Myers Squibb/HTG relationship, and we are excited to continue as a partner with Bristol-Myers Squibb’s translational research team,” said John Lubniewski, chief business officer for HTG.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.